{"id":"https://openalex.org/W7204996631","doi":"https://doi.org/10.26434/chemrxiv.15008183/v1","title":"In Silico Repurposing of Nilotinib as a Type II Tyrosine Kinase Inhibitor to Overcome C797S-Mediated Resistance in EGFR-Mutant Non-small cell lung cancer","display_name":"In Silico Repurposing of Nilotinib as a Type II Tyrosine Kinase Inhibitor to Overcome C797S-Mediated Resistance in EGFR-Mutant Non-small cell lung cancer","publication_year":2026,"publication_date":"2026-09-01","ids":{"openalex":"https://openalex.org/W7204996631","doi":"https://doi.org/10.26434/chemrxiv.15008183/v1"},"language":"en","primary_location":{"id":"doi:10.26434/chemrxiv.15008183/v1","doi":"https://doi.org/10.26434/chemrxiv.15008183/v1","is_oa":true,"landing_page_url":"https://doi.org/10.26434/chemrxiv.15008183/v1","pdf_url":"https://chemrxiv.org/doi/pdf/10.26434/chemrxiv.15008183/v1","source":{"id":"https://openalex.org/S4393918830","display_name":"ChemRxiv","issn_l":"2573-2293","issn":["2573-2293"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"posted-content"},"volume":null,"type":"preprint","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://chemrxiv.org/doi/pdf/10.26434/chemrxiv.15008183/v1","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5149048159","display_name":"Yik Long Matthew Tsang","orcid":"https://orcid.org/0009-0002-9075-8140","observed_orcids":["https://orcid.org/0009-0002-9075-8140"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yik Long Matthew Tsang","raw_affiliation_strings":["HKUGA College"],"raw_orcid":"https://orcid.org/0009-0002-9075-8140","affiliations":[{"raw_affiliation_string":"HKUGA College","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5025851598","display_name":"J. Ng","orcid":"https://orcid.org/0009-0003-8689-3654","observed_orcids":["https://orcid.org/0009-0003-8689-3654"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Julian Ng","raw_affiliation_strings":["HKUGA College"],"raw_orcid":"https://orcid.org/0009-0003-8689-3654","affiliations":[{"raw_affiliation_string":"HKUGA College","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9560999870300293,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9560999870300293,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.041099999099969864,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nilotinib","display_name":"nilotinib","score":0.9850000143051147},{"id":"https://openalex.org/keywords/drug-repurposing","display_name":"drug repurposing","score":0.9860000014305115},{"id":"https://openalex.org/keywords/egfr-c797s-mutation","display_name":"C797S mutation","score":0.9390000104904175},{"id":"https://openalex.org/keywords/egfr-mutant-non-small-cell-lung-cancer","display_name":"EGFR-mutant non-small cell lung cancer","score":0.8769999742507935},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.8209999799728394},{"id":"https://openalex.org/keywords/type-ii-kinase-inhibitors","display_name":"type II kinase inhibitors","score":0.6359999775886536},{"id":"https://openalex.org/keywords/osimertinib-resistance","display_name":"osimertinib resistance","score":0.9419999718666077},{"id":"https://openalex.org/keywords/allosteric-inhibition","display_name":"allosteric inhibition","score":0.8980000019073486},{"id":"https://openalex.org/keywords/molecular-docking","display_name":"molecular docking","score":0.4569999873638153}],"concepts":[{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.7694000005722046},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.7113000154495239},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5680000185966492},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.5504000186920166},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5321000218391418},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5303000211715698},{"id":"https://openalex.org/C2775905019","wikidata":"https://www.wikidata.org/wiki/Q192572","display_name":"In silico","level":3,"score":0.5281999707221985},{"id":"https://openalex.org/C2780381907","wikidata":"https://www.wikidata.org/wiki/Q198728","display_name":"Ponatinib","level":5,"score":0.5253999829292297},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.522599995136261},{"id":"https://openalex.org/C103637391","wikidata":"https://www.wikidata.org/wiki/Q5308921","display_name":"Drug repositioning","level":3,"score":0.5156999826431274},{"id":"https://openalex.org/C41685203","wikidata":"https://www.wikidata.org/wiki/Q1974042","display_name":"Docking (animal)","level":2,"score":0.5045999884605408},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.4819999933242798},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.4799000024795532},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.475600004196167},{"id":"https://openalex.org/C166342909","wikidata":"https://www.wikidata.org/wiki/Q845326","display_name":"Allosteric regulation","level":3,"score":0.4341000020503998},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.42890000343322754},{"id":"https://openalex.org/C2777626846","wikidata":"https://www.wikidata.org/wiki/Q21506464","display_name":"Osimertinib","level":5,"score":0.4203000068664551},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.40939998626708984},{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.4074000120162964},{"id":"https://openalex.org/C2780333294","wikidata":"https://www.wikidata.org/wiki/Q7914515","display_name":"Vandetanib","level":4,"score":0.350600004196167},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.34689998626708984},{"id":"https://openalex.org/C2780586478","wikidata":"https://www.wikidata.org/wiki/Q4688818","display_name":"Afatinib","level":5,"score":0.3467000126838684},{"id":"https://openalex.org/C519536355","wikidata":"https://www.wikidata.org/wiki/Q21021151","display_name":"Repurposing","level":2,"score":0.33640000224113464},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.3109000027179718},{"id":"https://openalex.org/C74187038","wikidata":"https://www.wikidata.org/wiki/Q1418791","display_name":"Drug discovery","level":2,"score":0.30630001425743103},{"id":"https://openalex.org/C143065580","wikidata":"https://www.wikidata.org/wiki/Q3285695","display_name":"Mutant","level":3,"score":0.28839999437332153},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.2741999924182892},{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.2712000012397766},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.27079999446868896},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.26919999718666077},{"id":"https://openalex.org/C2778208673","wikidata":"https://www.wikidata.org/wiki/Q894611","display_name":"Bosutinib","level":5,"score":0.26919999718666077},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.25949999690055847},{"id":"https://openalex.org/C182707283","wikidata":"https://www.wikidata.org/wiki/Q7315622","display_name":"Resistance mutation","level":5,"score":0.25519999861717224},{"id":"https://openalex.org/C150109051","wikidata":"https://www.wikidata.org/wiki/Q3630494","display_name":"Autophosphorylation","level":4,"score":0.2542000114917755},{"id":"https://openalex.org/C2780430158","wikidata":"https://www.wikidata.org/wiki/Q7685902","display_name":"Target protein","level":3,"score":0.25099998712539673},{"id":"https://openalex.org/C101544691","wikidata":"https://www.wikidata.org/wiki/Q420511","display_name":"Receptor tyrosine kinase","level":3,"score":0.25040000677108765}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.26434/chemrxiv.15008183/v1","doi":"https://doi.org/10.26434/chemrxiv.15008183/v1","is_oa":true,"landing_page_url":"https://doi.org/10.26434/chemrxiv.15008183/v1","pdf_url":"https://chemrxiv.org/doi/pdf/10.26434/chemrxiv.15008183/v1","source":{"id":"https://openalex.org/S4393918830","display_name":"ChemRxiv","issn_l":"2573-2293","issn":["2573-2293"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.26434/chemrxiv.15008183/v1","doi":"https://doi.org/10.26434/chemrxiv.15008183/v1","is_oa":true,"landing_page_url":"https://doi.org/10.26434/chemrxiv.15008183/v1","pdf_url":"https://chemrxiv.org/doi/pdf/10.26434/chemrxiv.15008183/v1","source":{"id":"https://openalex.org/S4393918830","display_name":"ChemRxiv","issn_l":"2573-2293","issn":["2573-2293"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7204996631.pdf","grobid_xml":"https://content.openalex.org/works/W7204996631.grobid-xml"},"referenced_works_count":17,"referenced_works":["https://openalex.org/W2025816743","https://openalex.org/W2035495099","https://openalex.org/W2105668062","https://openalex.org/W2130479394","https://openalex.org/W2145177236","https://openalex.org/W2145968308","https://openalex.org/W2159013299","https://openalex.org/W2166084034","https://openalex.org/W2169678694","https://openalex.org/W2400274474","https://openalex.org/W2593436234","https://openalex.org/W3009999522","https://openalex.org/W3014572135","https://openalex.org/W3097145107","https://openalex.org/W3128646645","https://openalex.org/W3168436232","https://openalex.org/W4410800318"],"related_works":["https://openalex.org/W4285223925","https://openalex.org/W4386790853","https://openalex.org/W3008952686","https://openalex.org/W2887271393","https://openalex.org/W2770240948","https://openalex.org/W4285246790","https://openalex.org/W4402046978","https://openalex.org/W2400274474","https://openalex.org/W2554688226","https://openalex.org/W4395678079"],"abstract_inverted_index":{"Drug":[0],"resistance":[1,309],"due":[2],"to":[3,48,60,66,102,106,130,165,245,272,279],"mutations":[4],"in":[5,17,53,81,191,204,225,289,292,310],"the":[6,18,91,112,138,161,166,199,202,233,307],"epidermal":[7],"growth":[8],"factor":[9],"receptor":[10,132],"(EGFR)":[11],"remains":[12,125],"a":[13,76,145,242,249,264,300],"major,":[14],"well-characterized":[15],"bottleneck":[16],"targeted":[19,304],"therapy":[20],"of":[21,74,85,140,148],"non-small":[22],"cell":[23],"lung":[24],"cancer":[25],"(NSCLC).":[26],"Among":[27],"these":[28],"mutations,":[29],"C797S,":[30],"emerging":[31],"after":[32],"treatment":[33],"with":[34,108,144,168,198,227,256],"third-generation":[35],"tyrosine":[36],"kinase":[37,203],"inhibitors":[38,87,159],"(TKIs)":[39],"such":[40],"as":[41,111],"Osimertinib":[42],"\u2014":[43],"prevents":[44,214],"covalent":[45],"drug":[46,275],"binding":[47,104,163,216],"EGFR":[49,92,234,255],"protein":[50,235],"and":[51,62,136,170,217,266,291],"results":[52],"current":[54],"therapies":[55,305],"ineffective.":[56],"This":[57,212],"study":[58,298],"aims":[59],"identify":[61],"repurpose":[63,280],"(Originally":[64],"used":[65,101,190],"treat":[67],"other":[68],"conditions)":[69],"potential":[70],"FDA-approved":[71,178,184],"TKIs":[72],"capable":[73],"overcoming":[75],"particular":[77],"C797S":[78,257],"mutation":[79,258],"through":[80],"silico":[82],"molecular":[83],"docking":[84,142],"52":[86],"(Type":[88],"I\u2013VI)":[89],"against":[90,306],"T790M/C797S":[93],"double":[94],"mutant":[95],"(PDB:":[96],"5ZWJ).":[97],"AutoDock":[98],"Vina":[99],"was":[100],"evaluate":[103],"affinities":[105],"EGFR,":[107,167,200],"EAI045":[109],"serving":[110],"reference":[113],"fourth-generation":[114],"inhibitor":[115,188],"for":[116,151,254,302],"validation":[117,294],"because":[118],"it":[119],"shows":[120],"promising":[121,243],"allosteric":[122],"inhibition":[123],"but":[124],"limited":[126],"by":[127,231,277],"its":[128,205],"inability":[129],"prevent":[131],"dimerization.":[133],"Results":[134,237],"compared":[135,271],"confirmed":[137],"simulation":[139],"our":[141],"model":[143],"self-docking":[146],"baseline":[147],"\u201310.46":[149],"kcal/mol":[150],"EAI045.":[152,181],"Generally,":[153],"screening":[154],"revealed":[155],"that":[156,173,239],"Type":[157,185],"II":[158,186],"exhibited":[160],"strongest":[162],"affinity":[164],"Nilotinib":[169,240],"Altiratinib":[171,174],"(Note":[172],"is":[175,241,295],"not":[176],"an":[177,183],"drug)":[179],"outperforming":[180],"Nilotinib,":[182],"Bcr-Abl":[187],"originally":[189],"chronic":[192],"myeloid":[193],"leukemia":[194],"(CML),":[195],"displays":[196],"hydrogen-bonding":[197],"sustaining":[201],"inactive":[206],"DFG-out":[207],"conformation":[208],"when":[209],"it\u2019s":[210],"binding.":[211],"mechanism":[213],"ATP":[215,229],"stops":[218],"auto":[219],"phosphorylation,":[220],"allowing":[221],"inhibitory":[222],"effects":[223],"even":[224],"environments":[226],"high":[228],"concentration":[230],"inhibiting":[232],"orthosterically.":[236],"show":[238],"candidate":[244],"be":[246],"repurposed":[247],"into":[248],"4th":[250],"generation":[251],"(Post-Osimertinib)":[252],"TKI":[253],"NSCLCs.":[259],"As":[260],"repurposing":[261],"drugs":[262,281],"have":[263],"quicker":[265],"cheaper":[267],"administrative+pre-clinical":[268],"testing":[269],"process":[270],"de":[273],"novo":[274],"discoveries,":[276],"aiming":[278],"we":[282],"can":[283],"accelerate":[284],"clinical":[285],"translation.":[286],"While":[287],"further":[288],"vitro":[290],"vivo":[293],"necessary,":[296],"this":[297],"provides":[299],"foundation":[301],"developing":[303],"C797S-mediated":[308],"advanced":[311],"NSCLC.":[312]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-09-02T00:00:00"}